Lucid Group (NASDAQ:LCID) 주식

LUCID GROUP INC

Lucid Group

Lucid Gr

Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations and through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.

LM22_GTLaunch_GTP_v1cc_03_Track

News

LCID

루시드 그룹(NASDAQ:LCID) 주가는 목요일(29일)에 회사 관련 뉴스가 많지 않았지만 급락세를 보였다. 이번 하락은 전기차 제조 부문에 영향을 미치는 더 광범위한 문제와 관련이 있는 것으로 보인다.

루시드, 전기차 업계 역풍 속 목요일 주가 8% 하락

Selective,Focus,Of,The,Byd,Vs,Tesla,Logo,On,A

Travel

Markets

ETFs

BYDDF

DRIV

HAIL

RIVN

TSLA

퓨처펀드의 매니징 파트너인 게리 블랙에 따르면, 중국 경쟁사의 가파른 할인 발표 이후 테슬라(NASDAQ:TSLA) 주가에 어려운 한 주가 될 수 있다.무슨 일 있었나: 게리 블랙은 월요일(26일) 엑스(X)를 통해 경쟁이 치열한 전기차 시장의 최근 가격 전쟁과 이것이 테슬라에 미치는 영향에 대한 우려를 언급했다. 그는 중국 자동차 제조업체인 BYD(OTC:BYDDF)와 최근 발표한 전기차 프랜차이즈 전반에 걸친 6%에서 20%에 이르는 할인을 지적했다.

게리 블랙 &#34;BYD 가격인하는 테슬라에 위협...머스크의 귀환은 큰 의미 없어&#34;

chart

Analyst Color

Equities

Large Cap

Sector ETFs

Broad U.S. Equity ETFs

Hedge Funds

Econ #s

Analyst Ratings

FSLR

Market Vectors ETF Trust Market Vectors Gold Miners

MEDP

MRNA

First Trust NASDAQ-100 Technology Index Fund

QTEC

S&amp;P 500 지수가 4월 이후 23% 급반등한 이후, 헤지펀드들은 투자자들이 관세 완화 랠리의 지속 가능성을 의심하는 가운데 주식에 대한 약세 베팅을 기록적인 수준으로 늘리고 있다. 

헤지펀드들, 주식에 대한 매도 포지션을 기록적으로 늘려

Lucid Group Inc

B of A Securities analyst Justin Post maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $230 to $248.

Price Target

AMZN

B of A Securities Maintains Buy on Amazon.com, Raises Price Target to $248

Piedmont Office Realty Trust Announced That It Has Completed Over 500,000 Square Feet Of Leasing Thus Far In The Second Quarter, With 350,000 Square Feet Related To New Tenants

VIAV

Inertial Labs, A VIAVI Solutions Announced The Launch Of A Visual-aided Inertial Navigation System (VINS) That Enables Aircraft To Maintain Accurate Flightpaths When No Reliable GPS/GNSS Signal Is Available

Liquidia Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Liquidia is scheduled to make its first commercial shipment of YUTREPIA&#x2122; (treprostinil) inhalation powder, marking the first time YUTREPIA will be available to be prescribed to patients at specialty pharmacies. This milestone was achieved only five business days following the U.S. Food and Drug Administration (FDA) approval of YUTREPIA on May 23, 2025, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

LQDA

Liquidia Begins Shipping Newly Approved Yutrepia for Rare Lung Diseases Just Days After FDA OK

B of A Securities analyst Ronald Epstein upgrades Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) from Neutral to Buy and raises the price target from $185 to $260.

Upgrades

B of A Securities Upgrades Boeing to Buy, Raises Price Target to $260

<ul>
<li>Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p&lt;0.0001)</li>
<li>Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continues</li>
<li>The safety profile of atacicept was favorable, and comparable to placebo</li>
<li>Vera plans to meet with FDA in the coming weeks to discuss these results and the regulatory pathway; Vera currently plans to submit a Biologics License Application (BLA) for accelerated approval to the FDA in 4Q 2025; ORIGIN 3 trial continues with two-year results expected in 2027</li>
<li>Vera will host a conference call and webcast at 8:00 am ET on Monday, June 2 &nbsp;</li>
</ul>
BRISBANE, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) today announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy (IgAN) in adults.
Participants treated with atacicept achieved a 46% reduction from baseline in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR), with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p&lt;0.0001) at week 36. For other prespecified endpoints, atacicept treatment also demonstrated results that were consistent with or better than those previously observed in the ORIGIN Phase 2b trial.1 The safety profile of atacicept in this analysis was favorable, and comparable to placebo. Vera plans to share these results with the FDA in the coming weeks, and full results will be submitted to the American Society of Nephrology Kidney Week.

VERA

Vera Therapeutics Says Atacicept ORIGIN Phase 3 Trial Meets Primary Endpoint Of Reduction In UPCR For IgAN Treatment; Vera Currently Plans To Submit BLA For Accelerated Approval To FDA In 4Q 2025

Southwest Airlines And China Airlines Group, A Taiwan-based Carrier, Are In Discussions To Create An Interline Partnership In Early 2026, With Published Connections Expected To Go On Sale Later This Year

Asset Sales

GPUS

Hyperscale Data Announced The Sale Of Its Minority Equity Interest In A Privately Held Pharmaceutical Company For Gross Proceeds Of $4.65M In Cash

HC Wainwright &amp; Co. analyst Brandon Folkes initiates coverage on Cardiol Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>) with a Buy rating and announces Price Target of $9.

Initiation

CRDL

HC Wainwright & Co. Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $9

HC Wainwright &amp; Co. analyst Brandon Folkes assumes PolyPid (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) with a Buy rating and announces Price Target of $11.

PYPD

HC Wainwright & Co. Assumes PolyPid at Buy, Announces Price Target of $11

Goldman Sachs analyst Jordan Alliger upgrades Knight-Swift (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) from Neutral to Buy and raises the price target from $45 to $65.

Goldman Sachs Upgrades Knight-Swift to Buy, Raises Price Target to $65

Goldman Sachs analyst Jordan Alliger upgrades Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) from Neutral to Buy and raises the price target from $24 to $32.

SNDR

Goldman Sachs Upgrades Schneider National to Buy, Raises Price Target to $32

KVUE

Kenvue Earns Spot On Fortune 500, Citing Strong Global Sales And Iconic Brand Portfolio

On Friday, May 30, U.S. markets closed mixed. The S&amp;P 500 ended flat but logged its strongest monthly gain since late last year, fueled by easing trade tensions, upbeat earnings, and subdued inflation. The Nasdaq also posted a solid monthly rise. Markets fluctuated on Trump&#8217;s conflicting trade signals, while investors held firm on rate cut expectations this fall.
In economic data, Consumer sentiment was revised to 52.2 in May from 50.8, while the Chicago PMI dropped to 40.5 from 44.6, indicating softer manufacturing.
Most S&amp;P 500 sectors ended lower Friday, led by losses in energy, consumer discretionary, and tech. Consumer staples and utilities outperformed, closing higher.
The Dow closed higher by 0.13% at 42,270.07, the S&amp;P 500 declined 0.01% to 5,911.69, and the Nasdaq fell 0.32% to 19,113.77.
Asia Markets Today
<ul class="wp-block-list">
<li>On Monday, Japan&#8217;s Nikkei 225 closed 1.32% lower at 37,463.50, led by losses in the Paper &amp; Pulp, Transport and Communication sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 fell 0.24%, ending the session at 8,414.10, led by losses in the Energy, Resources, Metals &amp; Mining sectors.</li>
<li>India&#8217;s Nifty 50 was down 0.13% at 23,157.97, and Nifty 500 rose 0.14% to 22,833.45.</li>
<li>China&#8217;s market was closed for the Dragon Boat Festival holiday.</li>
<li>Hong Kong&#8217;s Hang Seng closed the session 0.57% lower at 23,157.97.</li>
</ul>
Eurozone at 05:45 AM ET
<ul class="wp-block-list">
<li>The European STOXX 50 index was down 0.80%.</li>
<li>Germany&#8217;s DAX index declined 0.72%.</li>
<li>France&#8217;s CAC 40 fell 0.69%.</li>
<li>U.K.&#8217;s FTSE 100 index traded lower by 0.11%.</li>
</ul>
Commodities at 05:45 AM ET
<ul class="wp-block-list">
<li>Crude Oil WTI was trading higher by 3.57% at $62.97/bbl, and Brent was up 3.35% at $64.88/bbl.</li>
<li>Oil prices rose as OPEC+ kept July output hikes steady at 411,000 bpd. Tight supply, strong demand, and U.S. fuel concerns also supported the rally.</li>
<li>Natural gas rose 4.53% to $3.603.</li>
<li>Gold traded higher by 1.67% to $3,371.21, Silver rose 1.22% to $33.428, and Copper was up 4.66% to $4.8955.</li>
<li>Gold prices rose in Asian trade Monday amid renewed U.S.-China trade tensions and haven demand.</li>
</ul>
U.S. Futures at 05:45 AM ET
Dow Jones futures slid 0.50%, the S&amp;P 500 declined 0.57%, and the Nasdaq 100 was down 0.73%.
Forex at 05:45 AM ET
<ul class="wp-block-list">
<li>The U.S. Dollar Index declined 0.59% to 98.74, USD/JPY was down 0.81% to 142.89, and USD/AUD fell 0.79% to 1.5427.</li>
<li>The U.S. dollar fell Monday amid Trump&#8217;s tariff threats, China&#8217;s pushback, recession fears, and rising fiscal concerns. Rate-cut bets and safe-haven doubts added further pressure.</li>
</ul>
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Slide, Oil Gains 3% - Global Markets Today While US Slept

Needham analyst Serge Belanger maintains Liquidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) with a Buy and raises the price target from $25 to $32.

Needham Maintains Buy on Liquidia, Raises Price Target to $32

Goldman Sachs analyst Jordan Alliger upgrades Werner Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) from Sell to Buy and raises the price target from $25 to $39.

WERN

Goldman Sachs Upgrades Werner Enterprises to Buy, Raises Price Target to $39

CANG

Cango Enters Definitive Agreement With Founders And EWCL For $70M Class B Share Sale

BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>), a leading food technology company specializing in its patented GentleDry&#x2122; dehydrated snacks and ingredients, announces the execution of a strategic agreement with Kaufman Kapital LLC, resulting in a $1 million cash infusion through the early exercise of existing warrants. The agreement also includes amendments to existing financing terms that strengthen BranchOut's balance sheet, allow for debt repayment and extend key debt maturities.
Under the terms of the agreement, Kaufman Kapital will exercise in full an existing warrant to purchase 1,000,000 shares of BranchOut's common stock, providing the Company with $1,000,000 in cash proceeds no later than June 16, 2025.
In addition, the parties agreed to the following amendments:
<ul>
<li>Extension of the maturity date of the $3.4 million Senior Secured Convertible Promissory Note from December 31, 2025 to December 31, 2026.</li>
<li>Extension of the maturity date on the remaining $875,000 balance of the original $1.2 million Kaufman Senior Secured Promissory Note to December 31, 2025.</li>
<li>Extension of the expiration date of a separate warrant to purchase 500,000 shares to December 31, 2026 &nbsp;</li>
</ul>
"This Agreement reflects the strong confidence Kaufman Kapital has in our long-term growth strategy and operational execution," said Eric Healy, CEO of BranchOut Food. "The warrant exercise provides us with additional capital, while the note extensions improve our financial flexibility and strengthen our balance sheet."
Kaufman Kapital's decision to exercise its warrant ahead of schedule and extend key financing terms reflects continued confidence in BranchOut's trajectory. "We've been closely following BranchOut's progress, and the execution we're seeing across both operations and commercial growth is outstanding," said a spokesperson for Kaufman Kapital. "Our early exercise of the warrant reflects our strong confidence in the team, the business model, and the long-term opportunity. We're bullish on where BranchOut is headed and proud to support their continued momentum."
The $1 million in proceeds from the warrant exercise will be used to pay down outstanding debt obligations as part of BranchOut's broader initiative to eliminate all current liability notes payable by the end of 2025. This strategic use of capital reflects the Company's commitment to strengthening its balance sheet and positioning itself for sustained growth.

BranchOut Food Gets $1M Boost From Kaufman Kapital to Pay Down Debt and Fuel Growth

The new facility expands the Company's three loan agreements to a maximum borrowing capacity from $14.2 million to $23.0 million and extends the maturity date under each respective loan agreement from October 1, 2025 to April 30, 2027.
The additional borrowing capacity provides Solésence with significant financial flexibility to support its strategic objectives, including procurement of key raw materials and supplies at favorable pricing, improvement of lead times associated with packaging and product launches, and empowerment of the company's brand partners to drive product adoption.

Health Care

General

SLSN

Solésence Entered Into Amendments To Its Existing Loan Agreements, Providing Increased Borrowing Capacity To Support The Execution Of Strategic Objectives

Offerings

Press Releases

Lucid Group, Inc. Announces Proposed Convertible Senior Notes Offering

Lucid Group, Inc. Prices $1,000,000,000 Convertible Senior Notes Offering

Lucid Group, Inc. Announces Closing of Private Offering of $1.1 Billion of Convertible Senior Notes Due 2030

Lucid to Acquire Select Facilities and Assets Previously Belonging to Nikola Corporation, Will Extend Offers to 300+ Former Nikola Employees

Introducing the 2026 Lucid Gravity Grand Touring: A Force of Attraction Like Nothing Else in Nature

GraniteShares 2x Long LCID Daily ETF (LCDL) and GraniteShares 2x Long RIVN Daily ETF (RVNL) Launch Today.

Lucid and Saudi Arabia's KAUST Announce Strategic Partnership to Advance EV Technology Leadership and Grow Autonomous Driving and Advanced Driver Assist System Capabilities

Lucid Strengthens Leadership Team as Company Prepares for Growth

Earnings

Lucid Announces First Quarter 2025 Financial Results

Lucid Opens New Jersey Studio, Service, and Delivery Center for Area Customers

LCDL

RVNL

Cenntro

Chijet Motor Company, Inc. - Ordinary Shares

Chijet Motor Co

ECD Automotive Design, Inc. - Common Stock

ECD Automotive Design

Envirotech Vehicles

Ford Motor

Faraday Future Intelligent Electric Inc. - Class A Common Stock

Faraday Future

Fly-E Group

General Motors

Honda Motor Co

Li Auto Inc. - American Depositary Shares

Li Auto

Lotus Technology Inc. - American Depositary Shares

Lotus Technology

Mullen Automotive

NIO Inc. American depositary shares, each representing one Class A ordinary share

NWTN

Polestar Automotive Holding UK Limited - Class A ADS

Polestar Automotive

Polestar Automotive Holding UK Limited - Class C-1 ADS (ADW)

Rivian Automotive, Inc. - Class A Common Stock

Rivian Automotive

Thor Industries

Toyota Motor

Tesla

VinFast Auto

Winnebago Industries

Workhorse Gr

XPeng Inc. American depositary shares, each representing two Class A ordinary shares

XPeng

ZEEKR Intelligent Technology Holding Limited American Depositary Shares (each representing ten (10) Ordinary Shares)

Comments

Lucid Group

뉴스

파트너 / 기고자

벤징가 글로벌